Phio Pharmaceuticals Corp.
PHIOHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePhio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. The $9.9M market capitalization puts PHIO squarely in micro-cap range for its industry. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Market Cap
$9.9M
Beta
0.84
P/E (TTM)
—
P/E (Fwd)
-1.40
EPS (TTM)
$-1.30
EPS (Fwd)
$-0.61
ROE
-113.7%
ROA
-65.8%
Cash
$13.0M
Total Debt
$0
Free CF
-$7.7M
52W Change
-59.8%
Annual Financials
Cash vs Debt
Where PHIO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PHIO finished 20.18% below its 150-day moving average ($1.09) and 20.91% below its 200-day moving average ($1.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PHIO overbought or oversold?
At the October 20, 2026 close, PHIO's RSI(14) was 18.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Phio Pharmaceuticals Corp. reports $13.0M in cash and $0 in total debt. Free cash flow is running at -$7.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -113.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PHIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.